5.420USD+7.33%Mkt Cap: 7.92M USDP/E: —Last update: 2026-05-22
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap7.92M USD
Enterprise Value4.66M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.85M USD
Revenue/Share—
Last Price5.420 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.95
PEG—
EV/EBITDA-0.28
EV/Revenue—
P/S—
P/B58.05
EPS (TTM)-24.12
EPS (Forward)-0.39
52W Range
1.90027% of range14.76
52W High14.76 USD
52W Low1.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-350.48%
ROA-183.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.81M USD
CapEx (TTM)18.18K USD
FCF Margin—
FCF Yield-112.40%
Net Debt-2.72M USD
Net Debt/EBITDA0.16
Balance Sheet
Debt/Equity0.07
Current Ratio0.89
Quick Ratio0.64
Book Value/Sh0.0870 USD
Cash/Share2.019 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 22, 2025
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.1.46M
Float1.29M
Insiders0.55%
Institutions12.03%
Short Interest
Short Ratio1.7d
Short % Float4.86%
Short % Out.4.80%
Shares Short38.97K
Short (prev mo.)54.01K
Technical
SMA 503.420 (+58.5%)
SMA 2005.739 (-5.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.91M
Avg Vol (10d)86.13K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—